Aurinia Pharmaceuticals Inc (AUPH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, AUPH scores 77 out of 100, earning a B+ grade and the verdict label "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

• Fundamental Cash Engine: 13 / 20 (ROIC 16.5%; FCF yield 5.92%). This is the cash-generation view. The ROIC and FCF yield figures indicate the business is currently producing returns, though the pillar score sits in the middle of its range.
• Whale 13F Flow: 14 / 20 (institutional accumulation and options positioning). The score reflects moderate institutional support. The source does not provide the underlying 13F holdings detail, so the magnitude of accumulation cannot be verified here.
• Insider Conviction: 17 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the strongest of the market-signal pillars, suggesting insider and disclosed-trade activity is net supportive, though the individual trades are not itemized in the source.
• Macro Regime Fit: 15 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock is modeled to move in line with the broad market, so it neither amplifies nor dampens market swings.
• Forensic Balance Sheet: 18 / 20 (Altman Z 8.33; Piotroski F 7/9; Debt/Equity 0.5). This is the highest-scoring pillar. An Altman Z of 8.33 and Piotroski F of 7 out of 9 point to strong financial health, and Debt/Equity of 0.5 indicates moderate leverage.

For a prospective investor, the upside drivers are the balance-sheet strength and the supportive insider and institutional signals. The valuation tradeoff is that the stock trades at a trailing P/E of 8 and a forward P/E of 6.7, which can reflect either undervaluation or market skepticism about durability; the source does not resolve which. The 13/20 cash-engine score signals that cash generation, while present, has not yet reached the strength of the balance-sheet pillar. These are analytical observations, not personalized advice.

Per the SEC financials, revenue rose from $175.5M in FY 2023 to $283.1M in FY 2025, and operating income moved from a loss of $-91.7M to $104.9M over the same span. Per the market data, gross margin is 88.5%, operating margin 37.1%, and net margin 68%, with ROIC at 16.5%. The Altman Z-Score of 8.33 and Piotroski F-Score of 7/9 are cited in the RQD pillar detail. Debt/Equity is 0.5 per that same detail; the debt line in the SEC financials is not reported.

• Catalyst (GREEN): A headline reports the company raised its 2026 revenue forecast to $325 million–$330 million.
• Earnings: A headline reports AUPH topped Q3 earnings estimates; a separate headline reports Q3 earnings were expected to decline, and another notes the stock price slipped after Q3 earnings strength.
• Market wire items (YELLOW): Multiple aggregator items cover market action and institutional positioning without specific new figures.
• Proprietary signals: None were provided in the Butterfly Supply-Chain Graph.

Risk watch items: the conflicting earnings headlines warrant verification against primary filings, and the source does not confirm which characterization is current.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream/downstream dependencies, sector correlations, or 2nd-order bottlenecks.

• What are the company's specific products, and what share of the FY 2025 revenue comes from each?
• Which Q3 earnings characterization is accurate, given conflicting headlines?
• What is the reported debt balance, and what drives the 0.5 Debt/Equity figure?
• What is the underlying 13F institutional holding change and the composition of Form 4 insider trades?
• What is the EPS for the reported fiscal periods, which is listed as N/A?